Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide
Nupur Greene,1 Keiko Higuchi,1 Katalin Bognar,2 Eunice Chang,2 Michael S Broder2 1Neurology & Immunology (N&I), Sanofi, Cambridge, MA, USA; 2Real World Evidence, PHAR (Partnership for Health Analytic Research), Beverly Hills, CA, USACorrespondence: Nupur Greene, Global HEVA Business Partner,...
Saved in:
Main Authors: | Greene N (Author), Higuchi K (Author), Bognar K (Author), Chang E (Author), Broder MS (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States
by: Araujo L, et al.
Published: (2023) -
Subtypes of relapsing-remitting multiple sclerosis identified by network analysis
by: Quentin Howlett-Prieto, et al.
Published: (2023) -
The condition of the cardiovascular system in patients with relapsing-remitting multiple sclerosis
by: O. A. Traktirskaya, et al.
Published: (2019) -
An update of teriflunomide for treatment of multiple sclerosis
by: Oh J, et al.
Published: (2013) -
Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study
by: Krisztina Bencsik, et al.
Published: (2022)